Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 62 of 317 for:    colon cancer | ( Map: Canada )

Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02045030
Recruitment Status : Terminated (Drug (Aflibercept) no longuer available for the study)
First Posted : January 24, 2014
Last Update Posted : November 16, 2016
Sponsor:
Collaborators:
Sanofi
Regeneron Pharmaceuticals
Quebec Clinical Research Organization in Cancer
Information provided by (Responsible Party):
CR-CSSS Champlain-Charles-Le Moyne

Brief Summary:

This is a Phase II multi-center exploratory study to identify biomarkers predictive of clinical response to aflibercept in patients with metastatic colorectal cancer who have failed first-line therapy, consisting of an oxaliplatin-containing regimen in combination with bevacizumab. Patients will consent to a needle core biopsy of a liver metastatic lesion prior to starting treatment and blood samples will be collected from study patients during treatment.

An exploratory pharmacoeconomic analysis will be performed to evaluate productivity loss, quality of life and resource utilization while on treatment with aflibercept.


Condition or disease Intervention/treatment Phase
Metastatic Colorectal Cancer Drug: aflibercept + FOLFIRI Phase 2

Detailed Description:

This is a Phase II multi-center exploratory study to identify biomarkers predictive of clinical response to aflibercept in patients with metastatic colorectal cancer who have failed first-line therapy, consisting of an oxaliplatin-containing regimen in combination with bevacizumab. Patients will consent to a needle core biopsy of a liver metastatic lesion prior to starting treatment. This study will be open primarily at sites conducting the Q-CROC-01 study (NCT00984048), in which colorectal cancer patients receiving standard first-line treatment undergo a biopsy of a liver metastatic lesion before treatment and at resistance. The post-first-line treatment biopsy will be used as the pre-treatment biopsy for this trial. For patients not participating in the Q-CROC-01 study, patients will be required to undergo a liver needle core biopsy of a metastatic lesion before study treatment.

Biopsies and blood samples will be collected from all study patients. An exploratory pharmacoeconomic analysis will be performed to evaluate productivity loss, quality of life and resource utilization while on treatment with aflibercept.

A total of 52 patients will be enrolled, primarily at centers participating in the Q-CROC-01 study. The trial will close enrolment when 42 evaluable pre-treatment tumor biopsy samples have been obtained. Accrual of the total patient population is estimated to take 24-36 months with the estimated start date being February 2014.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer Who Have Failed First-Line Therapy
Study Start Date : January 2014
Actual Primary Completion Date : November 2016
Actual Study Completion Date : November 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: aflibercept and FOLFIRI
aflibercept and FOLFIRI
Drug: aflibercept + FOLFIRI
Aflibercept (Sanofi and Regeneron) targets the Vascular endothelial growth factor (VEGF) pathway that is a composite decoy receptor based on VEGFR-1 and VEGFR-2 fused to an Fc segment of IgG1. In pre-clinical assessments, aflibercept results in stronger angiogenesis inhibition than bevacizumab, exhibiting at least 100-1000 times higher affinity to the circulating VEGFs. It is postulated that in vivo, the binding of these ligands to aflibercept results in the blockade of tumor angiogenesis along with pruning of existing tumor vascular elements and reduction of VEGF-driven vascular permeability. The expected outcome is reduced growth of primary and metastatic tumors by impeding the density of tumor vasculature and diminishing the abnormal leakiness of tumor vessels that supply matrix components to the cancer.
Other Names:
  • aflibercept
  • FOLFIRI




Primary Outcome Measures :
  1. A biomarker (in blood or tissue) that may be predictive of level of response to aflibercept [ Time Frame: 3 years ]
    A biopsy from a liver metastasis will be taken at baseline for discovery of biomarkers that correlate with response to aflibercept. Genomic material (DNA and RNA) will be isolated from all biopsies. Batched analysis will be performed at the end of the study with the evaluable samples for multiplex biomarker discovery. Patient's biomarker status at baseline will be correlated with treatment effect on PFS and response (including response rate and disease control rate) to explore which biological targets may be particularly important in defining the appropriate treatment population for aflibercept.


Secondary Outcome Measures :
  1. Progression free survival (PFS) [ Time Frame: Time from registration to progressive disease (up to 3 years) ]
    The time from the date of registration until the date of radiological disease progression assessed by RECIST 1.1 or until death due to any cause, even in the absence of radiological progression.

  2. Response rate [ Time Frame: 3 years ]
    Defined as complete response (CR) and partial response (PR)

  3. Disease control rate [ Time Frame: 3 years ]
    Defined as complete response (CR) + partial response (PR) + stable disease (SD).

  4. Number of participants with adverse events [ Time Frame: 3 years ]
    Assessment of safety profile of aflibercept in combination with FOLFIRI: report of Adverse Events according to the NCI's Common Toxicity Criteria version 4.0

  5. The quality of life impact of treating with FOLFIRI in combination with Aflibercept [ Time Frame: From date of registration until progression of disease assessed up to 36 months ]
    Quality of life will be evaluated by questionnaires completed by the patient.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically or cytologically proven adenocarcinoma of the colon or rectum, with at least one liver metastasis site available for biopsy.
  2. Patients must have received only one prior chemotherapeutic regimen for metastatic disease. This prior chemotherapy must be an oxaliplatin containing regimen (in combination with bevacizumab). Patients who did not receive bevacizumab in their first-line treatment regimen may also be considered.
  3. Metastatic disease that is not amenable to potentially curative treatment.
  4. Measurable metastatic disease and evaluable disease.
  5. ECOG 0 or 1.
  6. Normal coagulation profile (PT, PTT, INR).
  7. Provide written consent after the investigational nature, study design, risks and benefits of the study have been explained.
  8. Age ≥ 18 years.

Exclusion Criteria:

  1. More than 1 prior chemotherapy regimen for metastatic colorectal cancer. Previous adjuvant FOLFOX based chemotherapy is allowed.
  2. Relapse from adjuvant treatment within 6 month of completion of adjuvant chemotherapy.
  3. Less than 42 days elapsed from prior major surgery to the time of registration.
  4. Inadequate or unusable tissue as the only tissue available for biopsy.
  5. Any of the following within 3 months of registration: Grade 3-4 gastrointestinal bleeding/hemorrhage, diverticulitis, pulmonary embolism, inflammatory or infections bowel disease, treatment resistant peptic ulcer disease, colitis, erosive esophagitis or gastritis, uncontrolled thromboembolic event.
  6. Prior intolerance to bevacizumab due to toxicity.
  7. Known dihydropyrimidine dehydrogenase (DPD) deficiency.
  8. Gilbert's Syndrome.
  9. Occurrence of deep vein thrombosis within 4 weeks, prior to registration.
  10. Any of the following within 6 months prior to registration; myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, NYHA class III or IV congestive heart failure, stroke or transient ischemic attack.
  11. Contraindication to any of the components of the FOLFIRI chemotherapy regimen, as per investigators' judgement.
  12. Inadequate bone marrow function as follows:

    • Absolute neutrophil count (ANC) < 1.5x 109/L
    • Platelet count < 100 x 109/L
    • Hemoglobin < 90 g/L
  13. Inadequate liver function test:

    • Total bilirubin > 1.5 x ULN
    • Transaminases > 3 x ULN (if liver metastasis are present, 5 x ULN)
    • Alkaline phosphatase > 3 x ULN (if liver metastases are present, 5 x ULN)
  14. Contraindication to aflibercept. Including:

    • Urine protein-creatinine ratio (UPCR) > 1 on morning spot urinalysis or proteinuria >500 mg/24-h
    • Serum creatinine > 1.5 x upper limit of normal (ULN). If creatinine 1.0 - 1.5 x ULN, creatinine clearance, calculated according to Cockroft-Gault formula, < 60 ml/min will exclude the patient.
    • History of uncontrolled hypertension, defined as blood pressure > 150/100 mgHG (grade ≥ 2 according to NCIC CTCAE v. 4.0), or systolic blood pressure > 180 mmHG when diastolic blood pressure < 90 mmHG, on at least 2 repeated determinations on separate days within 3 months prior to study enrollment.
    • Patients on anticoagulant therapy with unstable dose of warfarin and/or having an out-or-therapeutic range INR (>3) within the 4 weeks prior to study entry.
    • Evidence of clinically significant bleeding diathesis or underlying coagulopathy (eg. INR>1.5 without vitamin K antagonist therapy), non-healing wound.
  15. Known active brain metastases or meningeal disease.
  16. Female patients who are pregnant or breastfeeding.
  17. Patients of reproductive potential (male and female) who do not agree to use an accepted form of contraception during the study period and up to 6 months following completion of study treatment.
  18. Concurrent treatment with other anti-cancer therapy (palliative radiation is allowed but patients must have a metastatic site available for biopsy that has not been irradiated).
  19. Known infection with HIV.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02045030


Locations
Layout table for location information
Canada, Quebec
CSSS Champlain-Charles-Le Moyne
Greenfield Park, Quebec, Canada, J4V 2H1
Hôpital Maisonneuve-Rosemont
Montreal, Quebec, Canada, H1T 2M4
Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2
Hôpital du Sacré-Coeur de Montréal
Montréal, Quebec, Canada, H4J 1C5
Sponsors and Collaborators
CR-CSSS Champlain-Charles-Le Moyne
Sanofi
Regeneron Pharmaceuticals
Quebec Clinical Research Organization in Cancer
Investigators
Layout table for investigator information
Principal Investigator: Benoit Samson, MD CSSS Champlain-Charles-Le Moyne

Publications:
Layout table for additonal information
Responsible Party: CR-CSSS Champlain-Charles-Le Moyne
ClinicalTrials.gov Identifier: NCT02045030     History of Changes
Other Study ID Numbers: Q-CROC-04
First Posted: January 24, 2014    Key Record Dates
Last Update Posted: November 16, 2016
Last Verified: August 2016
Keywords provided by CR-CSSS Champlain-Charles-Le Moyne:
metastatic
colorectal
cancer
aflibercept
FOLFIRI
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Colonic Diseases
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases